Preservation of renal function with early use of mtor inhibitor or late change in immunosuppression in liver transplantation

twice daily; The primary outcome was the patient adherence to the medication regime. Secondary outcomes were as follows: safety (measured as rate of medication complications), graft survival and pharmacokinetics. Taking clinical heterogeneity in trial participants and treatments into account, a random-effect model was chosen for the meta-analyses. Results: Change of the immunosuppression regime showed improved adherence of patients according to individual criteria and the Basel Assessment of Adherence Scale to Immunosuppressives. There was no statistically significant increase in Serious Adverse Events (SAEs) or rejection. Conclusion: Based on validated adherence evaluation and SAEs the change in Tacrolimus-based immunosuppression is safe and promotes adherence in liver transplant patients.